BMJ · 1993 · 48 citations · 5 references
MedicineNeurologyPharmacotherapyNeuroimmunologyNeuromuscular DisordersNeuropathologyNervous System PathologyPeripheral Nervous SystemGanglioside Antibody NeuropathyGuillain-barré Syndrome Pathogenesis
Exogenous gangliosides are marketed in several countries and used to treat many neurological diseases. Although no well designed clinical trial has con- vincingly shown their efficacy in diseases of the peripheral or central nervous system, they are widely prescribed, at least in Italy. An estimated 4-1% of the population in Rome were prescribed gangliosides in 1989,1 and in 1991 around 4-2% of the 687 401 people from five local health districts in the Emilia Romagna region received the drugs (N Montanaro, et al, personal communication).
5
Gordon Guyatt · JAMA · 1992 · 4.2K citations
Bovine gangliosides and acute motor polyneuropathy.
Albert Figueras, Francisco J. Morales‐Olivas, Dolors Capellà et al. · BMJ · 1992 · 79 citations · Full text
Medicine, Neurology, Neuroscience +14
Guillain-Barré syndrome and parenteral gangliosides
Norman Latov, CarolL. Koski, PatriciaA. Walicke et al. · The Lancet · 1991 · 63 citations
Ganglioside Therapy and Guillain-Barré Syndrome
Enrico Granieri, Ilaria Casetta, Vittorio Govoni et al. · Neuroepidemiology · 1991 · 56 citations
Is routine induction of labour at term ever justified?
L. Cardozo · BMJ · 1993 · 29 citations · Full text